<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title10.html">
                                    Title 10
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/10CFR35.html">Part 35
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 35.300  Use of unsealed byproduct material for which a written
                            </h3>
                            <p class="depth0">A licensee may use any unsealed byproduct material prepared for medical use and for which a written directive is required that is--</p><p class="depth1"><em>(a)</em> Obtained from:</p><p class="depth2"><em>(1)</em> A manufacturer or preparer licensed under Sec. 32.72 of this chapter or equivalent Agreement State requirements; or</p><p class="depth2"><em>(2)</em> A PET radioactive drug producer licensed under Sec. 30.32(j) of this chapter or equivalent Agreement State requirements; or</p><p class="depth1"><em>(b)</em> Excluding production of PET radionuclides, prepared by:</p><p class="depth2"><em>(1)</em> An authorized nuclear pharmacist;</p><p class="depth2"><em>(2)</em> A physician who is an authorized user and who meets the requirements specified in Sec. Sec. 35.290, 35.390, or</p><p class="depth2"><em>(3)</em> An individual under the supervision, as specified in Sec. 35.27, of the authorized nuclear pharmacist in paragraph (b)(1) of this section or the physician who is an authorized user in paragraph (b)(2) of this section; or</p><p class="depth1"><em>(c)</em> Obtained from and prepared by an NRC or Agreement State licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA; or</p><p class="depth1"><em>(d)</em> Prepared by the licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA.
[67 FR 20370, Apr. 24, 2002, as amended at 68 FR 19324, Apr. 21, 2003; 71 FR 15009, Mar. 27, 2006; 72 FR 55932, Oct. 1, 2007]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
